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Abstract 
Background: Bacillus Calmette–Guérin (BCG) is a live-attenuated 
vaccine used world-wide for prevention of tuberculosis disease. In 
some immunocompromised hosts it has the potential to cause 
disease. As with other members of the M. tuberculosis complex it has 
the potential for acquiring drug resistance. 
Methods: We reviewed 10 years of paediatric clinical BCG strains 
referred to our clinical microbiology laboratory in Oxford where they 
underwent whole genome sequencing. We present a case series 
comparing clinical, pathogen genetic and pathogen phenotypic data, 
and consider the clinical implications. 
Results: We identified 15 BCG isolates from 8 children under 16 years 
old. Only one child had clinical disease with the other seven reported 
as local inoculation-site reactions. Case 1 suffered disseminated 
disease secondary to an undiagnosed IL-12/IFNγ receptor defect and 
the BCG isolates evolved two different rifampicin resistance 
mutations. Across all 15 isolates, phenotypic resistance to each first 
line drug was seen.  
Conclusions: BCG is a safe and effective vaccine in children. Most 
clinical specimens in our series were not related to disease. However, 
in the context of rare pathogen-specific immunocompromise, BCG can 
cause pathology and acquire drug resistance under selection from 
therapy.
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Introduction
The Bacillus Calmette–Guérin (BCG) vaccine has been in use 
worldwide for many years as prophylaxis against Mycobac-
terium tuberculosis infection. It is a live-attenuated vaccine 
derived from many cell culture passages of Mycobacterium 
bovis. There are multiple different M. bovis BCG strains1 but 
the Danish Staten Serum Institute (SSI) 1331 strain has been 
the most widely used in the United Kingdom (UK).
All M. bovis BCG strains are inherently resistant to pyrazi-
namide. The in vitro susceptibility of vaccine strains to other 
antibiotic agents has been investigated by previous studies1,2. 
Unusually, the Danish BCG strain 1331 has only intermediate 
isoniazid susceptibility (sensitive at 0.4 μg/ml but resistant 
at 0.1 μg/ml)1 and is resistant to ethionamide. In vivo, however, 
serum concentrations of isoniazid would often be >0.1 μg/ml3 
and its low-grade resistance has not been considered a clinical 
problem. Alternative vaccine strains have occasionally been 
used during periods of interruption to the supply of the 
Danish 1331 preparation in the UK. These include the InterVax 
(Canada) BCG vaccine (Bulgarian substrain [Sofia] SL222)4 
and the Connaught strain2.
BCG adenitis following vaccination is relatively common, with 
an incidence of 1 in 1500–28005. The history has been well 
described, and local infection usually regresses spontaneously6. 
In contrast, disseminated BCG infection is extremely rare (esti-
mated to affect 3.4 children per million given BCG5) and is 
characteristically associated with primary or secondary immu-
nodeficiency. There are no clear guidelines on how best to treat 
children with disseminated M. bovis BCG strain infection. 
However, treatment regimens generally include a prolonged 
course of rifampicin, isoniazid and ethambutol with adjust-
ments made according to antibiotic susceptibility testing, led 
by an expert in mycobacterial infection, similar to recommen-
dations for treating patients with multidrug-resistant (MDR) 
M. tuberculosis7.
In Oxfordshire, United Kingdom (UK), the annual incidence 
of TB is relatively low (approximately 4 per 100,000) and 
children are only given the BCG vaccine if they are in a 
high-risk group as defined by Public Health England (PHE) 
guidance8. This study was triggered by the isolation of a 
rifampicin-resistant BCG strain from a child in Oxfordshire 
who was vaccinated due to being in a high-risk epidemiologi-
cal group, and went on to develop disseminated BCG disease. To 
better contextualise this case, we sought to assess the antibiotic 
susceptibilities of other M. bovis BCG isolates from children 
submitted to our clinical microbiology laboratory.
Methods
Study population
This study was conducted at Oxford University Hospitals 
NHS Foundation Trust, UK, a large tertiary referral teaching 
hospital for which specialist services serve a population of 
approximately 2.5 million people. Clinical isolates referred 
to the regional laboratory at Oxford University Hospital NHS 
Foundation Trust, UK, and identified as Mycobacterium 
tuberculosis complex have been whole-genome-sequenced 
using Illumina technology since 20079. Following the iden-
tification of an index case of a child with disseminated BCG 
infection (‘Case one’), we used this sequence database to iden-
tify BCG isolates from children, and reviewed clinical notes 
and routine microbiology results of these cases.
Phenotypic susceptibility testing
Culture-based susceptibility testing was performed using liq-
uid culture (Bactec MGIT 960) at the Public Health England 
National Mycobacterial Reference Laboratory, London.
Mycobacterial sequencing
For isolates identified as BCG, Illumina reads were mapped 
to a Mycobacterium bovis reference genome (AF2122/97 
NC_002945.3) using Stampy (version 1.0.17), with repetitive 
regions masked. Variant calls were made using SAMtools 
mpileup (version 0.1.18), based on a minimum depth of 5X 
and at least one read on each strand. A mixed-call was assigned 
where the minority allele composed >10% of read depth10. 
Genotypic susceptibility predictions were based on a catalogue 
of resistance mutations previously described11.
Ethics approval
Our retrospective review of laboratory data did not require 
formal ethical approval but the Caldicott guardian for Oxford 
University Hospitals NHS Foundation Trust approved the study 
and we obtained written informed consent from the parents of 
our index case (‘Case one’). Mycobacterial sequencing was 
undertaken as part of service development within clinical 
microbiology.
Case report and results
Clinical context of M. bovis samples
We identified 15 clinical samples from eight children <16 years 
old (Table 1). Case one was a girl of Pakistani descent who 
first presented at 4 months of age. She had been vaccinated 
routinely with BCG (Danish strain 1331) soon after birth as she 
was from a high-risk epidemiological group. She developed 
disseminated BCG infection and was subsequently diagnosed 
with an Interleukin-12 receptor B1 (IL-12 RB1) gene mutation, 
which is known to increase susceptibility to mycobacterial 
disease12. The samples from the remaining seven cases all arose 
from either injection site collections or local adenitis, and all 
arose in children who had received the same vaccine strain.
Antibiotic management of M. bovis in an 
immuncompromised host
Case one initially received rifampicin (15 mg/kg daily), 
isoniazid (10 mg/kg daily), pyrazinamide (35 mg/kg daily) and 
ethambutol (20 mg/kg daily) for presumed M. tuberculosis 
infection. Following identification of the isolate as M. bovis 
by line-probe assay in the National Mycobacterial Refer-
ence Laboratory, London, approximately two months into 
therapy, pyrazinamide was stopped. A month later, phenotypic 
susceptibilities became available, suggesting resistance to 
ethambutol. This agent was therefore switched to moxifloxacin 
(10 mg/kg daily). She received 15 months of therapy and then 
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Table 1. Summary of 12 M. bovis BCG strain isolates from 8 children in a UK cohort. All children in this series had 
been immunised with the Danish 1331 M.bovis BCG strain.
Phenotypic drug 
sensitivity profile
Site of BCG detection Clinical diagnosis Underlying 
condition
Outcome INH RIF EMB PZA
Case 1 Left axillary LN 2013 BCG adenitis
IL12Rb1 defect
Ongoing 
infection
S S R R
Left axillary LN 2013 BCG adenitis
Gastric aspirate 2014 Disseminated BCG S S R R
Gastric aspirate 2014 Disseminated BCG
Right axillary LN 2014 Disseminated BCG S S S R
Cervical LN 2015 Relapse disseminated 
BCG
S R S R
Pus, abdominal wall 2017 Relapse disseminated 
BCG
S S S R
Case 2 Left axillary LN 2013 BCG adenitis Metabolic disorder Resolved infection
S S S R
Case 3 Tissue L arm 2013 BCG adenitis Nil Resolved 
infection
S S R R
Axillary swab 2013 BCG adenitis Nil Resolved 
infection
Case 4 Left axillary LN 2013 BCG adenitis Nil Resolved 
infection
S S S R
Case 5 BCG site swab 2015 BCG site abscess Nil Resolved 
infection
R S S R
Case 6 Left axillary LN 2007 BCG adenitis HIV Resolved 
infection
S S S R
Case 7 Gastric aspirate/PEG swab 
2009
Abscess over BCG scar Nil Resolved 
infection
S S S R
Case 8 BCG scar 2007 ND ND ND S S S R
Key: LN, lymph node; RIF, Rifampicin; INH, isoniazid; PZA, pyrazinamide; EMB, ethambutol; ND, No data available. Blank indicates not tested.
commenced azithromycin (10 mg/kg daily, three days a week) 
for prophylaxis against non-tuberculous mycobacterial infection. 
She subsequently relapsed with disseminated BCG infection 
nine months after stopping initial antimycobacterial treatment, 
requiring multiple surgical procedures (drainage of abdominal 
collections) and prolonged antibiotic therapy, which are still 
ongoing three years later.
Antibiotic susceptibility of M. bovis isolates in Case one
Phenotypic susceptibility profiles are summarised in Table 1. 
All 5 of 7 isolates with phenotypic results from this child 
were reported as isoniazid susceptible. In total, two of five 
isolates were reported as phenotypically resistant to ethambutol. 
In the penultimate isolate (2015), in vitro rifampicin resistance 
was also reported. This corresponded to the identification 
of a rifampicin resistance mutation (rpoB D435V) in the 
2015 isolate, a well characterised mutation in the rifampicin 
resistance determining region that is the target of the widely-
used MTB/RIF Xpert assay13. Interestingly, after rifampicin 
therapy was stopped and the patient suffered a further relapse 
in 2017, the organism was reported to be phenotypically 
susceptible and the D435V mutation was no longer present, 
although an alternative rpoB mutation (L430P) was present on 
WGS, and was also detected by Xpert MTB/RIF at the reference 
laboratory. The fact that the subsequent isolate had a different 
mutation is suggestive of a significant ongoing within-host 
selective pressure. That the rifampicin phenotype was susceptible 
despite the L430P resistance mutation is not unprecedented13.
Antibiotic susceptibility of other M. bovis isolates
Among the other seven children from whom BCG was isolated, 
one exhibited phenotypic resistance to ethambutol and one to 
isoniazid (Table 1). Despite resistance being reported to all 
first-line antibiotics within our set of isolates, no single isolate 
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was resistant to more than two drugs (i.e. more than one in 
addition to pyrazinamide). We were unable to identify any 
genetic basis for phenotypic resistance to isoniazid or etham-
butol, despite searching through a list of known resistance-
mechanisms with 94–98% sensitivity in M. tuberculosis 
infection13. As expected, based on derivation from a single 
vaccine strain, the paediatric isolates were all closely related, 
with a maximum of seven SNPs separating any two samples 
(Figure 1). Interestingly, we observed phenotypic variation in 
drug susceptibility even among isolates that are genomically 
indistinguishable.
Sequence data
All raw sequence data have been uploaded to the ENA and are 
available under the project number PRJNA548242.
Discussion
We have confirmed that isolation of M. bovis BCG strain from 
clinical samples is rare, with only eight positive cases recorded 
over an 11-year period in a large teaching hospital laboratory. 
The majority of these reflected local adenitis, which is a 
well-recognised complication of vaccination14,15. There was only 
one case of disseminated M. bovis BCG, which occurred in a 
child with an immunodeficiency known to increase susceptibility 
to severe mycobacterial infection12.
This epidemiology reflects that which has been previously 
described; in a previous study in London 98% of BCG compli-
cations were local, with only 2% having systemic sequelae14. 
Likewise, National UK Medicines and Healthcare Products 
Regulatory Agency (MHRA) data from 2013/14 reported 41 
adverse incidents related to the BCG vaccine, of which only 
two were disseminated BCG infection, the rest being local 
complications16. The Australian mycobacterial reference labora-
tory detected 24 M. bovis BCG isolates in 2009 (nine in children 
under six years old), with the majority of these being repre-
senting vaccine site abscesses (n=13)17. Similarly, in the USA 
between 2006–2013 there were only 73 cases of M. bovis BCG 
strain isolated compared with 91,985 cases of M. tuberculosis18. 
In this study, we are able to draw on full-length sequence 
data for M. bovis to assess the presence of drug-resistance 
mutations and correlate these with phenotypic resistance 
testing. Rifampicin resistance in M. bovis (BCG) has been 
Figure 1. Maximum likelihood phylogenetic tree based on whole genome sequences of BCG isolates. Tip labels describe the case 
number, site of isolation, susceptibility profile ordered as isoniazid, rifampicin, ethambutol, pyrazinamide, and year of isolation. Scale bar 
shows a branch length of 0.5 SNPs.
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reported previously, in each case in an immunocompromised 
child, including its emergence on treatment19–21. Case one in our 
series had multiple isolates tested, with genotypic rifampicin 
resistance twice selected for, but only detected phenotypically 
once. This may be due to variations in the subpopulations of 
M. bovis organisms that are sampled in a patient with a high 
bacterial burden, or reflect antibiotic pressure (the rifampicin 
our patient had been receiving was stopped when the resistant 
isolate was detected). The presence of phenotypic resistance 
to isoniazid and ethambutol despite the absence of any iden-
tifiable genetic predictors of resistance is interesting: it might 
represent hitherto unrecognised mechanisms of resistance, or 
alternatively error in phenotypic determination of resistance. 
The latter is suggested by the fact that in vitro susceptibility 
reporting varies despite indistinguishable genomic sequences.
In our small series of cases we have observed in vitro resistance 
to each first-line anti-tuberculosis drug, despite BCG being a 
laboratory strain that is administered to patients. Despite 
known low-level isoniazid resistance in the Danish SSI 1331 
BCG strain19, to our knowledge no underlying mechanism for 
this has been identified. Whatever the explanation, as far as we 
know the presence of resistance to any drug has only been 
clinically relevant in Case one in our cohort, whose primary 
problem was one of immunodeficiency predisposing to severe 
mycobacterial infection. Since local infection commonly either 
resolves spontaneously, or can be managed by aspiration or 
surgical excision14,15, the antibiotic resistance profile may not be 
clinically relevant to developing a safe management plan.
Although the BCG vaccine is contraindicated in patients with 
immunodeficiencies, in the UK infants in high-risk groups 
for developing tuberculosis are usually vaccinated soon after 
birth, before any immunodeficiency will have become clinically 
apparent. In the cases with local vaccine site collections or 
adenitis, it could be argued that laboratory diagnosis did not 
inform the management, and thus in only one of the seven 
cases with clinical information available was the mycobacterial 
culture and/or sequence data clinically useful. 
It is not known how many doses of BCG are given to UK 
children per year, but according to Public Health England 
(PHE) data for high-risk areas, it will be considerably more than 
30,000 doses22. A recent systematic review and meta-analysis23 
of the effect of BCG vaccination in children demonstrated a 
19% protective efficacy against tuberculosis infection among 
vaccinated children after exposure compared with unvacci-
nated children, and protection by BCG against progression from 
infection to active disease of 58%. Thus, that only one case had 
invasive disease from all the children receiving the BCG in our 
large population catchment area, suggests BCG is safe, and 
that it is the host response that is important in the development 
of disease rather than any specific attribute of the vaccine strain. 
In view of the dramatic changes in the development of whole 
genome sequencing of mycobacteria in the last few years, routine 
phenotypic antibiotic resistance testing has been discontinued 
in England in favour of genotypic testing. On the one hand 
this will provide more reproducible results, but on the other 
hand it will not detect resistance due to unknown mechanisms, 
such as that reported for isoniazid in the Danish BCG strain. 
However, work to enrich our knowledgebase of molecular 
resistance determinants is accelerating13 and the clinical 
relevance of this low-level isoniazid resistance that is only 
rarely detected even by phenotypic methods is questionable. 
Phenotyping only detected this purported isoniazid resistance in 
one of our clinical isolates.
In summary, we have shown isolation of M. bovis BCG strain 
is rare, and that the BCG vaccine is safe and well-tolerated in 
immunocompetent children. Only in the setting of profound 
immunocompromise do we see molecular and phenotypic 
rifampicin resistance emerging, most likely facilitated by a 
large bacillary burden. Because invasive disseminated BCG 
disease is rare, reporting and data sharing is important to allow 
assimilation of experience, particularly with respect to unusual 
cases of antibiotic resistance.
Data availability
Underlying data
European Nucleotide Archive: Clinical Mycobacterium bovis 
(BCG) isolates and antibiograms: a case series from children in 
Oxfordshire, 2007-2017. Accession number PRJNA548242; https://
identifiers.org/ebi/ena.embl:PRJNA548242.
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Mark P. Nicol   
Department of Microbiology, The University of Western Australia, Crawley, WA, Australia 
This interesting and well-written case report (and series) complements our understanding of the 
risks associated with BCG vaccination. 
 
I have several minor queries/suggestions:
As noted by reviewer Ben Marais, it would be useful to know the specifics of INH 
susceptibility testing (concentration[s] of INH used), given the varying susceptibility 
reported, and the background low level resistance expected in this BCG strain. 
 
1. 
Similarly, it would be fascinating to know whether there is evidence of a resistant sub-
population within the BCG vaccine stock - i.e., whether we're vaccinating children with a 
heteroresistant strain. 
 
2. 
I'm not sure that statements about the rarity of BCG-related adverse events is fully 
supported by the data, as there are only broad estimates of country-level denominators. 
Further, it is not completely clear whether all M. tuberculosis complex isolates over the 
period of study underwent WGS, or only a subset.  
 
3. 
Similarly, the statement that "it is the host response that is important in the development of 
disease rather than any specific attribute of the vaccine strain" does not appear to be fully 
substantiated by the evidence presented. All adverse events were associated with one 
strain, and there are no data given on the numbers of children vaccinated with different 
strains within the study region and period. 
 
4. 
I am not sure that I fully agree with the statement that "in cases with local vaccine site 
collections or adenitis, it could be argued that laboratory diagnosis did not inform the 
management". Ruling out other causes of infection may have been clinically useful in the 
management of these children.
5. 
 
Is the background of the case’s history and progression described in sufficient detail?
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Yes
Are enough details provided of any physical examination and diagnostic tests, treatment 
given and outcomes?
Yes
Is sufficient discussion included of the importance of the findings and their relevance to 
future understanding of disease processes, diagnosis or treatment?
Yes
Is the case presented with sufficient detail to be useful for other practitioners?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: clinical microbiology, tuberculosis, microbiome
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Reviewer Report 20 November 2020
https://doi.org/10.21956/wellcomeopenres.17888.r41519
© 2020 Marais B. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Ben J. Marais   
Westmead Children's Hospital and the Marie Bashir Institute for Infectious Diseases and 
Biosecurity, University of Sydney, Sydney, NSW, Australia 
Well written and interesting case series. Informed discussion and balanced conclusion. 
 
Minor comments for consideration:
Variability in DST and SNPs in Danish strain 1331 BCG (without nay treatment selection) is 
interesting. DST variability may be explained by inaccurate phenotypic results - it would be 
good to know the level of resistance detected in these instances. It is also relevant for INH, 
given that resistance was VERY rarely detected phenotypically, which is unexpected if tested 
at 0.1ug/ml. 
1. 
For SNP variability the question remains if this represents post administration diversity or 
diversity in the 'vaccine stock' itself. Have the authors tested 'vaccine stock' (straight from 
the vail) to assess possible SNP variability?
2. 
In the discussion it would be good to provide an estimated denominator for the statement 
that BCG adverse effects were VERY rare. Do we know how many BCGs (roughly) 
3. 
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were administered to children in the study area over the study period?
Any suggestions on how the single case could/should have been dealt with differently to 
prevent the recurrent relapses observed? Should the initial treatment period have been 
extended in light of the immune abnormality and ineffectiveness of PZA?
4. 
Can we accept 'significant within host selective pressure' as a likely explanation in a child 
with significant immune compromise? It seems as if treatment induced selective pressure, 
differential drug penetration and selective sampling of bacterial sub-populations offer the 
most likely explanation in this instance.
5. 
 
Overall this is an informative and well-presented report that makes an important contribution to 
the existing literature. Consideration of minor comments above should help to refine it further.
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Are enough details provided of any physical examination and diagnostic tests, treatment 
given and outcomes?
Yes
Is sufficient discussion included of the importance of the findings and their relevance to 
future understanding of disease processes, diagnosis or treatment?
Yes
Is the case presented with sufficient detail to be useful for other practitioners?
Yes
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This is an interesting and well written case report highlighting the complexity of managing a rare 
case of disseminated BCG. It also showed the importance of phenotypic sensitivity testing to 
 
Page 10 of 11
Wellcome Open Research 2020, 5:242 Last updated: 25 NOV 2020
ensure the most appropriate anti-mycobacterial treatment course for this rare condition. It also 
explains why multiple drugs are included in regimens to treat patients such as these. The authors 
do not comment on toxicity/adverse drug reactions in this child. They also don't comment on drug 
levels - metabolism of rifampicin in children differs greatly to adults, and higher drug doses are 
required to achieve therapeutic drug levels - this child may have benefited from therapeutic drug 
monitoring - the authors could comment on its role in these complex cases. It may be that low 
levels of rifampicin contributed to the within-host selective pressure. 
 
As it is a case report, I would be interested to see more details on the clinical case, but understand 
why the authors have concentrated on the drug sensitivity element of the presentation - as this 
has relevance for the readers, in particular if they have a similar case in the future. I wonder if the 
team have considered the role of phage therapy for this child, as she seems to be still be on an 
antibiotic regimen 3 years later.  
 
Reporting rare cases such as these has value as clinical decisions are made on expert opinion, 
rather than evidence based data. This case will ensure future similar cases are considered in the 
context of drug sensitivity/resistance.  
 
It would be interesting for the authors to comment on screening for primary immune deficiencies 
and planned changes to BCG delivery in the UK. Of particular note, this child would not have been 
identified by TREC screening, so the case would not have been avoided.
 
Is the background of the case’s history and progression described in sufficient detail?
Yes
Are enough details provided of any physical examination and diagnostic tests, treatment 
given and outcomes?
Partly
Is sufficient discussion included of the importance of the findings and their relevance to 
future understanding of disease processes, diagnosis or treatment?
Yes
Is the case presented with sufficient detail to be useful for other practitioners?
Yes
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